Privileged Scaffolds in Drug Discovery is the most complete and up-to-date work in the area. Covering a wide range of privileged structures, it is a perfect reference for scientists involved in targeted drug development.
The editors recruited epserts from several prestigious Chinese institutions to cover the areas of antiviral drugs, chalcone, pyrimidine, (benz)imidazoles, natural product-derived privileged scaffolds, N-Sulfonyl carboxamides, kinase inhibitors, antitumor molecules, antineurodegenerative drugs, triazoles, oxazolidinone, indole and indoline scaffolds, tigliane diterpenoids, peptide and peptide-based drugs, quassinoids, and others including pseudonatural products, macrocycles, stable peptides and peptidomimetics. The book also explores scaffolds in drug molecules approved in recent years.
Privileged Scaffolds in Drug Discovery is a complete reference for researchers in drug discovery and organic synthesis, in academic and corporate settings, who are investigating privileged structures upon which to base new drugs. Researchers in medicinal chemistry and chemical biology will also find the contents of this book valuable.
1. Introduction - p. xxv 2. Chapter 1. Thiazole, a privileged scaffold in drug discovery - p. 1 3. Chapter 2. Chalcones: Diverse biological activities and structure–activity relationships - p. 21 4. Chapter 3. Privileged chalcone scaffolds in drug discovery - p. 41 5. The N-sulfonyl carboxamide moiety as a privileged structure in approved drugs - p. 65 6. Chapter 5. Scaffolds in cytotoxic drugs and novel antitumor molecules interacting with nucleic acids - p. 81 7. Chapter 6. Triazoles: a privileged scaffold in drug design and novel drug discovery - p. 105 8. Chapter 7. Oxazolidinone scaffolds in drug discovery and development - p. 117 9. Chapter 8. Indole and indoline scaffolds in drug discovery - p. 147 10. Chapter 9. Cyanopyridine as a privileged scaffold in drug discovery - p. 163 11. Chapter 10. Indazole as a privileged scaffold in drug discovery - p. 199 12. Chapter 11. (Benz)imidazoles: privileged scaffolds in medicinal chemistry - p. 227 13. Chapter 12. Tranylcypromine (TCP): a privileged scaffold for designing histone lysine demethylase 1 inhibitors - p. 257 14. Chapter 13. Applications of piperazine scaffold in drug design - p. 273 15. Chapter 14. Thiols as a privileged scaffold against metallo-β-lactamases - p. 301 16. Chapter 15. Tetrahydro-β-carboline scaffold in drug discovery - p. 319 17. Chapter 16. Benzoxaborole: a privileged scaffold for drug discovery - p. 335 18. Chapter 17. Privileged scaffolds in anti-diabetic drug discovery - p. 357 19. Chapter 18. Authentic HIV-1 integrase inhibitors for the treatment of HIV-1/AIDS - p. 377 20. Chapter 19. 2-Aminopyrimidine: a privileged scaffold in kinase drug discovery - p. 391 21. Chapter 20. Alzheimer's disease therapeutics: current strategies and future directions - p. 405 22. Chapter 21. Sulfonyl fluorides as warheads in drug discovery - p. 475 23. Chapter 22. α,β-Bifunctionalized carbonyl compounds as privileged motifs in drug discovery and their synthetic protocols - p. 483 24. Chapter 23. Diarylpyrimidines and related analogs as antiviral agents - p. 513 25. Chapter 24. Organic synthetic methodology-based new scaffolds in drug discovery - p. 543 26. Chapter 25. Natural resource of anti–human immunodeficiency virus leading compounds: tigliane diterpenoids - p. 565 27. Chapter 26. Biological phenethyl glycosides from plants - p. 587 28. Chapter 27. Triterpenoids and saponins in drug discovery - p. 613 29. Chapter 28. Casbene-derived diterpenoids - p. 673 30. Chapter 29. Quassinoids: phytochemistry and antitumor prospect - p. 691 31. Chapter 30. Structural diversity, biosynthesis, and biological functions of meroterpenoids from microbial metabolites - p. 717 32. Chapter 31. Glucocorticoid compounds in drug discovery by targeting glucocorticoid receptor protein - p. 781 33. Chapter 32. Peptide and peptide-based drugs - p. 795 34. Chapter 33. Stapled peptides for new drug discovery - p. 817 35. Chapter 34. Current status and trends in research and development of polypeptide drugs - p. 861 36. Chapter 35. Unique opportunities of metal scaffolds in drug design - p. 875 37. N-Heterocyclic carbene as privileged scaffold in medicinal inorganic chemistry - p. 901 38. Chapter 37. Selenium-containing heterocycles - p. 915 39. Chapter 38. Computational methods for scaffold hopping - p. 931 40. Index - p. 949
Privileged Scaffolds in Drug Discovery is the most complete and up-to-date work in the area. Covering a wide range of privileged structures, it is a perfect reference for scientists involved in targeted drug development.
The editors recruited epserts from several prestigious Chinese institutions to cover the areas of antiviral drugs, chalcone, pyrimidine, (benz)imidazoles, natural product-derived privileged scaffolds, N-Sulfonyl carboxamides, kinase inhibitors, antitumor molecules, antineurodegenerative drugs, triazoles, oxazolidinone, indole and indoline scaffolds, tigliane diterpenoids, peptide and peptide-based drugs, quassinoids, and others including pseudonatural products, macrocycles, stable peptides and peptidomimetics. The book also explores scaffolds in drug molecules approved in recent years.
Privileged Scaffolds in Drug Discovery is a complete reference for researchers in drug discovery and organic synthesis, in academic and corporate settings, who are investigating privileged structures upon which to base new drugs. Researchers in medicinal chemistry and chemical biology will also find the contents of this book valuable.
1. Introduction - p. xxv 2. Chapter 1. Thiazole, a privileged scaffold in drug discovery - p. 1 3. Chapter 2. Chalcones: Diverse biological activities and structure–activity relationships - p. 21 4. Chapter 3. Privileged chalcone scaffolds in drug discovery - p. 41 5. The N-sulfonyl carboxamide moiety as a privileged structure in approved drugs - p. 65 6. Chapter 5. Scaffolds in cytotoxic drugs and novel antitumor molecules interacting with nucleic acids - p. 81 7. Chapter 6. Triazoles: a privileged scaffold in drug design and novel drug discovery - p. 105 8. Chapter 7. Oxazolidinone scaffolds in drug discovery and development - p. 117 9. Chapter 8. Indole and indoline scaffolds in drug discovery - p. 147 10. Chapter 9. Cyanopyridine as a privileged scaffold in drug discovery - p. 163 11. Chapter 10. Indazole as a privileged scaffold in drug discovery - p. 199 12. Chapter 11. (Benz)imidazoles: privileged scaffolds in medicinal chemistry - p. 227 13. Chapter 12. Tranylcypromine (TCP): a privileged scaffold for designing histone lysine demethylase 1 inhibitors - p. 257 14. Chapter 13. Applications of piperazine scaffold in drug design - p. 273 15. Chapter 14. Thiols as a privileged scaffold against metallo-β-lactamases - p. 301 16. Chapter 15. Tetrahydro-β-carboline scaffold in drug discovery - p. 319 17. Chapter 16. Benzoxaborole: a privileged scaffold for drug discovery - p. 335 18. Chapter 17. Privileged scaffolds in anti-diabetic drug discovery - p. 357 19. Chapter 18. Authentic HIV-1 integrase inhibitors for the treatment of HIV-1/AIDS - p. 377 20. Chapter 19. 2-Aminopyrimidine: a privileged scaffold in kinase drug discovery - p. 391 21. Chapter 20. Alzheimer's disease therapeutics: current strategies and future directions - p. 405 22. Chapter 21. Sulfonyl fluorides as warheads in drug discovery - p. 475 23. Chapter 22. α,β-Bifunctionalized carbonyl compounds as privileged motifs in drug discovery and their synthetic protocols - p. 483 24. Chapter 23. Diarylpyrimidines and related analogs as antiviral agents - p. 513 25. Chapter 24. Organic synthetic methodology-based new scaffolds in drug discovery - p. 543 26. Chapter 25. Natural resource of anti–human immunodeficiency virus leading compounds: tigliane diterpenoids - p. 565 27. Chapter 26. Biological phenethyl glycosides from plants - p. 587 28. Chapter 27. Triterpenoids and saponins in drug discovery - p. 613 29. Chapter 28. Casbene-derived diterpenoids - p. 673 30. Chapter 29. Quassinoids: phytochemistry and antitumor prospect - p. 691 31. Chapter 30. Structural diversity, biosynthesis, and biological functions of meroterpenoids from microbial metabolites - p. 717 32. Chapter 31. Glucocorticoid compounds in drug discovery by targeting glucocorticoid receptor protein - p. 781 33. Chapter 32. Peptide and peptide-based drugs - p. 795 34. Chapter 33. Stapled peptides for new drug discovery - p. 817 35. Chapter 34. Current status and trends in research and development of polypeptide drugs - p. 861 36. Chapter 35. Unique opportunities of metal scaffolds in drug design - p. 875 37. N-Heterocyclic carbene as privileged scaffold in medicinal inorganic chemistry - p. 901 38. Chapter 37. Selenium-containing heterocycles - p. 915 39. Chapter 38. Computational methods for scaffold hopping - p. 931 40. Index - p. 949
